Avanos Medical, Inc.

NYSE:AVNS

Medical - Devices

Healthcare
$24.99 +0.22%

+$0.06 today

Market cap
$1.17B
Beta
1.57
P/E (TTM)
-16.7
EPS (TTM)
-$1.50
52W Low $9.30High $25.49

Volume 0.43M

Average 1.49M

AVNS Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Avanos Medical, Inc.NYSE: AVNS

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $93.8M rose 20.7% year over year, ahead of the +18.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 1.2% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.

Context

  • Cost of revenue amounted to 50.2% of revenue in FY2025, up 5.7 pp from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +20.7% holds above the trailing-twelve-month pace of +18.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$93.8M-1.2% QoQ
Last fiscal yearDec 2025
$352.2M+14.9% YoY
LTMMar 2026
$368.3M+18.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+20.7%——
1 year+14.9%——
3-year CAGR+6.7%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
352.2M USD
Year-over-year change
+14.9%
4-year CAGR
-0.9%

Cost of Revenue vs competitors

How AVNS compares with its peers on the latest reported figures

  • AVNS's LTM Mar 2026 cost of revenue of $368.3M is the 3rd highest of the 11 companies compared; the peer median is $98.92M.
  • Its year-over-year change of +18.2% is the 4th highest of 11, against a peer median of +1.8%.
  • Cost of revenue amounts to 51.4% of revenue for AVNS, versus a peer median of 50.0%.
AVNS Competitors Peer median
Cost of Revenue for AVNS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYHCommunity Health Systems, Inc.LTM Mar 2026$9.96B +35.0%+16.0%46.3%
VREXVarex Imaging CorporationLTM Apr 2026$569.8M +3.9%-1.3%66.4%
AVNSAvanos Medical, Inc.LTM Mar 2026$368.3M +18.2%+6.7%51.4%
BVSBioventus Inc.LTM Mar 2026$185.67M -0.4%+0.8%32.2%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$100.69M -21.2%+11.3%62.9%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$99.22M -12.1%-54.4%112.4%
CTKBCytek Biosciences, Inc.LTM Mar 2026$98.61M +11.1%+15.4%48.3%
BCYCBicycle Therapeutics plcLTM Mar 2026$71.03M -55.3%—111.9%
LABStandard BioTools Inc.LTM Mar 2026$44.6M -34.2%-11.1%51.7%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$15.51M +24.0%+26.7%38.2%
CBLLCeriBell, Inc.LTM Mar 2026$11.68M +28.7%+34.5%12.3%
Peer median (excluding AVNS) $98.92M+1.8%+11.3%50.0%

Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue744.6M684.1M673.3M687.8M701.2M
Cost of Revenue364.7M289.9M293.6M306.5M352.2M
Gross Profit379.9M394.2M379.7M381.3M349M
Gross Margin51.0%57.6%56.4%55.4%49.8%
Research & Development32.3M30.6M27.2M26.2M23.1M
Selling, General & Admin260.8M323.1M287.5M315.1M218.3M
Operating Expenses293.1M352.3M314.7M341.3M410.6M
Depreciation & Amortization38.3M41.1M43.5M45.5M29M
EBITDA48.9M77.8M50.6M(345.6M)(33.2M)
EBITDA Margin6.6%11.4%7.5%-50.2%-4.7%
Operating Income86.8M41.9M65M40M(61.6M)
Operating Margin11.7%6.1%9.7%5.8%-8.8%
Interest Income200K1.2M2.9M5.1M3.2M
Interest Expense3.3M10M15M12.2M4M
Other Income / Expenses(79.5M)(15.2M)(72.9M)(443.3M)(4.6M)
Income Before Tax7.3M26.7M(7.9M)(403.3M)(66.2M)
Pre-Tax Margin1.0%3.9%-1.2%-58.6%-9.4%
Income Tax Expense1M5.2M2M(17M)1.7M
Net Income6.3M50.5M(61.8M)(392.1M)(67.9M)
Net Margin0.8%7.4%-9.2%-57.0%-9.7%
EPS (Basic)0.131.08(1.33)(8.53)(1.46)
EPS (Diluted)0.131.07(1.33)(8.53)(1.46)
Weighted Avg Shares48.1M46.9M46.6M46M46.4M
Weighted Avg Shares (Diluted)48.6M47.3M46.6M46M46.4M

Avanos Medical, Inc.

NYSE:AVNS

Intrinsic Alpha fair value

Locked

Current Price

$24.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.